Payment overview · 2025
General Payments
$751.49
32 reported records · 11 companies
Healthcare provider profile · identity verified
John Liu, MD
Allopathic & Osteopathic Physicians|Family Medicine · HINSDALE, IL · NPI 1689770232
Verified facts
What the public records show
CMS Open Payments records show John Liu, MD received $751.49 in general payments during 2025 across 32 reported records.
Lilly USA, LLC accounted for 18.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Linzess, Ozempic.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Synthroid by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Symbicort by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Eliquis by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 188 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $142.21 | 18.9% | 6 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $116.65 | 15.5% | 5 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $109.63 | 14.6% | 5 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $83.12 | 11.1% | 3 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $81.92 | 10.9% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $65.20 | 8.7% | 3 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $61.29 | 8.2% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $33.91 | 4.5% | 2 | 2025 |
| RECORDATI_RARE_DISEASES_INC. | Unresolved — no canonical attribution shown | $22.07 | 2.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $18.14 | 2.4% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $17.35 | 2.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $751.49 | 32 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $116.18 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $116.18 | 5 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $87.74 | 4 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $83.12 | 3 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $83.12 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $50.16 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $50.16 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $50.16 | 2 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $47.62 | 2 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $40.28 | 2 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $34.17 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $33.91 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $33.91 | 2 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C., PFIZER INC. | $32.39 | 2 | 2025 |
Source payment records
|
|||||
| KRYSTEXXA Normalized: krystexxa |
Biological | Amgen Inc. | $28.91 | 1 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $27.12 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $26.31 | 1 | 2025 |
Source payment records
|
|||||
| KISUNLA Normalized: kisunla |
Drug | Lilly USA, LLC | $26.03 | 1 | 2025 |
Source payment records
|
|||||
| ISTURISA Normalized: isturisa |
Drug | RECORDATI_RARE_DISEASES_INC. | $22.07 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 188 | exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 12 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 81 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
188 | 43 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
188 | 43 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
13 | 13 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 379 | 118 |
| Levothyroxine Sodium | Levothyroxine Sodium | 273 | 78 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 261 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 246 | 74 |
| Furosemide | Furosemide | 230 | 69 |
| Pantoprazole Sodium | Pantoprazole Sodium | 226 | 72 |
| Losartan Potassium | Losartan Potassium | 191 | 54 |
| Eliquis | Apixaban | 188 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 185 | 57 |
| Lisinopril | Lisinopril | 169 | 53 |
| Simvastatin | Simvastatin | 167 | 46 |
| Gabapentin | Gabapentin | 163 | 52 |
| Escitalopram Oxalate | Escitalopram Oxalate | 158 | 52 |
| Metformin Hcl | Metformin Hcl | 137 | 42 |
| Alprazolam | Alprazolam | 134 | 32 |
| Sertraline Hcl | Sertraline Hcl | 132 | 50 |
| Omeprazole | Omeprazole | 123 | 45 |
| Metoprolol Tartrate | Metoprolol Tartrate | 116 | 44 |
| Tamsulosin Hcl | Tamsulosin Hcl | 115 | 36 |
| Hydrochlorothiazide | Hydrochlorothiazide | 110 | 34 |
| Potassium Chloride | Potassium Chloride | 98 | 33 |
| Tramadol Hcl | Tramadol Hcl | 92 | 26 |
| Trazodone Hcl | Trazodone Hcl | 90 | 28 |
| Allopurinol | Allopurinol | 88 | 29 |
| Lorazepam | Lorazepam | 87 | 18 |
| Ozempic | Semaglutide | 81 | 16 |
| Carvedilol | Carvedilol | 78 | 23 |
| Clopidogrel | Clopidogrel Bisulfate | 78 | 26 |
| Finasteride | Finasteride | 72 | 24 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 68 | 51 |
| Bupropion Xl | Bupropion Hcl | 64 | 21 |
| Torsemide | Torsemide | 63 | 19 |
| Azithromycin | Azithromycin | 61 | 43 |
| Memantine Hcl | Memantine Hcl | 60 | 19 |
| Clonazepam | Clonazepam | 58 | 17 |
| Hydralazine Hcl | Hydralazine Hcl | 58 | 17 |
| Warfarin Sodium | Warfarin Sodium | 58 | 18 |
| Famotidine | Famotidine | 52 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 51 | 22 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 50 | 22 |
| Diazepam | Diazepam | 50 | 15 |
| Zolpidem Tartrate | Zolpidem Tartrate | 50 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 49 | 15 |
| Cefdinir | Cefdinir | 47 | 31 |
| Prednisone | Prednisone | 47 | 31 |
| Donepezil Hcl | Donepezil Hcl | 46 | 16 |
| Fluoxetine Hcl | Fluoxetine Hcl | 43 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 43 | 13 |
| Spironolactone | Spironolactone | 43 | 17 |
| Alendronate Sodium | Alendronate Sodium | 41 | suppressed |
| Glimepiride | Glimepiride | 41 | 12 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | suppressed |
| Nystatin | Nystatin | 41 | 20 |
| Meloxicam | Meloxicam | 40 | 12 |
| Oxybutynin Chloride | Oxybutynin Chloride | 40 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 40 | 15 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 13 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 37 | 26 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 36 | 21 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 34 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 33 | 11 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 32 | suppressed |
| Atenolol | Atenolol | 32 | suppressed |
| Levetiracetam | Levetiracetam | 32 | suppressed |
| Methylprednisolone | Methylprednisolone | 32 | 26 |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 31 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 31 | 13 |
| Ketoconazole | Ketoconazole | 31 | 17 |
| Metformin Hcl Er | Metformin Hcl | 31 | 11 |
| Mirtazapine | Mirtazapine | 31 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 31 | 11 |
| Celecoxib | Celecoxib | 30 | suppressed |
| Bumetanide | Bumetanide | 29 | 11 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 29 | suppressed |
| Ezetimibe | Ezetimibe | 29 | 11 |
| Lovastatin | Lovastatin | 29 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 29 | 13 |
| Klor-Con M20 | Potassium Chloride | 28 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | 12 |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 26 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 26 | suppressed |
| Xarelto | Rivaroxaban | 25 | suppressed |
| Cephalexin | Cephalexin | 24 | 22 |
| Ibuprofen | Ibuprofen | 24 | suppressed |
| Synthroid | Levothyroxine Sodium | 24 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Digoxin | Digoxin | 22 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 21 | 16 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 21 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 20 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 20 | 11 |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Fluconazole | Fluconazole | 20 | 14 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 20 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 19 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 19 | suppressed |
| Baclofen | Baclofen | 18 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 18 | suppressed |
| Irbesartan | Irbesartan | 18 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 18 | 11 |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Januvia | Sitagliptin Phosphate | 17 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 17 | suppressed |
| Pregabalin | Pregabalin | 17 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 16 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 16 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 16 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 15 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 15 | suppressed |
| Levofloxacin | Levofloxacin | 15 | suppressed |
| Sucralfate | Sucralfate | 15 | suppressed |
| Temazepam | Temazepam | 15 | suppressed |
| Fentanyl | Fentanyl | 14 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 14 | suppressed |
| Nystop | Nystatin | 14 | suppressed |
| Olmesartan-Amlodipine-Hctz | Olmesartan/Amlodipin/Hcthiazid | 14 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 14 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 13 | suppressed |
| Febuxostat | Febuxostat | 13 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 12 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 12 | suppressed |
| Hydrocortisone | Hydrocortisone | 12 | suppressed |
| Invokamet | Canagliflozin/Metformin Hcl | 12 | suppressed |
| Linzess | Linaclotide | 12 | suppressed |
| Oxycontin | Oxycodone Hcl | 12 | suppressed |
| Risperidone | Risperidone | 12 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Amoxicillin | Amoxicillin | 11 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Erythromycin | Erythromycin Base | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Glipizide | Glipizide | 11 | suppressed |
| Klayesta | Nystatin | 11 | suppressed |
| Methocarbamol | Methocarbamol | 11 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 11 | suppressed |
| Mupirocin | Mupirocin | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Olanzapine | Olanzapine | 11 | suppressed |
| Polymyxin B Sul-Trimethoprim | Polymyxin B Sulf/Trimethoprim | 11 | suppressed |
| Ramipril | Ramipril | 11 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 11 | suppressed |
| Valsartan | Valsartan | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $751.49 · 32 records | Lilly USA, LLC | ABRYSVO, AIRSUPRA, AREXVY, CAPVAXIVE, COMIRNATY, CREON, Cologuard Collection Kit, ELIQUIS, EVENITY, FARXIGA, GARDASIL 9, ISTURISA, KISUNLA, KRYSTEXXA, LINZESS, MOUNJARO, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, SHINGRIX, VRAYLAR, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error